Harvard Bioscience (HBIO) Change in Accured Expenses (2010 - 2026)

Harvard Bioscience (HBIO) has reported Change in Accured Expenses for 17 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 19.77% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $2.0 million (up 185.42% YoY), while the FY2025 annual figure was $2.3 million, up 228.85% from the prior year.
• Change in Accured Expenses advanced to $1.2 million in Q1 2026 per HBIO's latest filing, from $797000.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $2.0 million in Q1 2024 and bottomed at -$2.3 million in Q2 2024.
• Historically, Change in Accured Expenses has averaged -$13294.1 across 5 years, with a median of -$28000.0 in 2023.
• On a YoY basis, Change in Accured Expenses climbed as much as 660.16% in 2024 and fell as far as 2555.32% in 2024.
• Harvard Bioscience's Change in Accured Expenses stood at $980000.0 in 2022, then plunged by 122.96% to -$225000.0 in 2023, then sank by 567.56% to -$1.5 million in 2024, then soared by 153.06% to $797000.0 in 2025, then jumped by 48.18% to $1.2 million in 2026.
• Business Quant data shows HBIO's Change in Accured Expenses at $1.2 million in Q1 2026, $797000.0 in Q4 2025, and -$271000.0 in Q3 2025.